The article focuses on how collateral benefits should be considered differently by Institutional Review Boards (IRBs) and Data Safety Monitoring Boards (DSMBs) in decentralized clinical trials (DCTs). Topics include the ethical implications of incorporating collateral benefits during ongoing trials, the risk of overvaluing these benefits in the face of emerging direct harms, and the distinct responsibilities of IRBs versus DSMBs in risk-benefit assessments.